{"result": "Here is a comprehensive summary of the data:\n\nAtezolizumab is a medication that has been studied in several papers and is an anti-PD-L1 immune checkpoint inhibitor. It was approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic triple-negative breast cancer. Additionally, atezolizumab is an immunotherapy drug that has been used in clinical trials.\n\nNote: I resolved the contradictions by combining the information from each description to provide a single, coherent summary.", "input": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we the have full context.\n\n#######\n-Data-\nEntities: \"\\\"ATEZOLIZUMAB\\\"\"\nDescription List: [\"\\\"Atezolizumab is a medication that was studied in several papers.\\\"\", \"\\\"Atezolizumab is an anti-PD-L1 immune checkpoint inhibitor that was approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic triple-negative breast cancer.\\\"\", \"\\\"atezolizumab is an immunotherapy drug used in clinical trials.\\\"\"]\n#######\nOutput:\n", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 500, "n": null}}